What is Cordlife Group Limited (CLIFF)?

Cordlife Group Limited (CLIFF) is a stock in the Healthcare sector, Medical - Diagnostics & Research industry. View full analysis on Stocks360.

What is the current price of CLIFF?

The current price of CLIFF is $0.13. Prices are updated in real time on Stocks360.

What is CLIFF's price-to-earnings (PE) ratio?

CLIFF's trailing twelve-month PE ratio is -2.90, based on current price and earnings per share data available on Stocks360.

What is CLIFF's market capitalization?

CLIFF's market capitalization is $32,884,284.00, placing it in the small-cap tier.

Cordlife Group Limited (CLIFF)

Stock analysis · OTC · Healthcare · Medical - Diagnostics & Research

$0.13

Market Cap

$32.88M

PE (TTM)

-2.90

EPS (TTM)

N/A

Dividend Yield

0.00%

Beta

0.67

Day Range

$0.09 – $0.13

52-wk Range

$0.07 – $0.15

Avg Volume

N/A

Volume

2.13K

Cordlife Group Limited (CLIFF) is a publicly traded company in the Healthcare sector. Latest price: $0.13. Market cap $32.88M. Trailing PE -2.90. Sign in to Stocks360 for full DCF valuation, fundamentals, technicals, and AI-driven analysis.

Get full analysis → Short-Term Analysis →

1-Year Price

2025-10-28 · $0.09 2026-10-26 · $0.13 (+42.40%)

Proprietary Signals

Signal snapshot temporarily unavailable.

About Cordlife Group Limited

As an investment holding company, Cordlife Group Limited offers cord blood banking solutions across various countries including Singapore, Hong Kong, India, Malaysia, and the Philippines, extending its reach globally. Its operations are structured into two distinct segments: Banking and Diagnostics. The Banking segment is dedicated to the processing and secure storage of stem cells derived from cord blood, cord lining, and cord tissue. Meanwhile, its Diagnostics arm delivers a suite of screening services, such as non-invasive prenatal testing, pediatric vision evaluations, and genetic and metabolic screenings for newborns. Furthermore, Cordlife extends its diagnostic offerings to include specialized procedures like preimplantation genetic screening, endometrial receptivity testing, pediatric allergen analysis, and genetic talent assessments. It also supports parents through "moms up," a mobile application providing valuable resources for pregnancy and parenting. Beyond its core medical services, the company engages in management, marketing, and property investment activities. Established in 2001, Cordlife Group Limited maintains its corporate headquarters in Singapore.

Valuation

Trailing twelve months. Multiples relative to current market price.
P/E (TTM)	-2.90×
P/S (TTM)	0.84×
P/B	0.31×
PEG	0.09×
P/FCF (TTM)	-31.61×
EV / EBITDA	-2.92×
EV / Sales	0.68×
Earnings Yield	-34.48%
Free Cash Flow Yield	-3.16%

Fundamentals

Trailing twelve months. Source: financial statements via market data.
Enterprise Value	$25.07M
Revenue (TTM)	$36.96M
Net Income (TTM)	-$10.69M
Free Cash Flow (TTM)	-$894.17K
Net Debt	-$5.94M
Working Capital	$54.41M
Gross Margin	56.65%
Operating Margin	-33.96%
Net Margin	-28.93%
Return on Equity	-10.28%
Return on Invested Capital	-7.26%